Dr. Takeshi Yoshimoto – Cancer – Best Researcher Award

Dr. Takeshi Yoshimoto - Cancer - Best Researcher Award

University of Tsukuba Hospital - Japan

Author Profile

SCOPUS

🎓 Early academic pursuits

 Dr. Takeshi Yoshimoto began his academic journey in the medical sciences with a strong foundation in clinical education. he earned his m.d. from hiroshima university faculty of medicine in march 2008, followed by a ph.d. from the graduate school of biomedical and health sciences, hiroshima university in august 2022. during his formative years, his curiosity about cerebrovascular diseases led him to explore genetics, biomarkers, and translational medicine, laying the groundwork for his future research focus, which indirectly intersects with diagnostic technologies resembling the precision systems used in power electronics.

đź§  Professional endeavors

Dr. Yoshimoto's career showcases a rich progression through esteemed institutions. from his early role as an intern at fukushima coop hospital, he gradually ascended through ranks at national cerebral and cardiovascular center, serving as resident, senior resident, Cancer and later as a medical doctor under  distinguished mentors like dr. ihara and dr. toyoda. he also contributed to academia at hiroshima university and currently serves as a lecturer in the department of stroke and cerebrovascular diseases at university of tsukuba hospital. his consistent clinical involvement paired with academic appointments underlines his dual commitment to patient care and neurological research.

🧬 Contributions and research focus

A pioneer in translational stroke research, dr. yoshimoto focuses on integrating genetics with acute stroke management. his primary research involves developing algorithms for selecting clot removal devices by identifying genetic variations, particularly the moyamoya-related rnf213 p.r4810k polymorphism. he explores the association between juvenile strokes and serum biomarkers. his projects are comparable in Cancer precision and application-oriented design to power electronics, highlighting his innovative integration of medical diagnostics and genetic profiling to improve acute care strategies.

🌍 Impact and influence

Dr. Yoshimoto’s work has had significant impact on cerebrovascular research, especially in japan. his dedication to exploring the genetic underpinnings of stroke has advanced understanding of moyamoya disease and enhanced patient stratification for endovascular therapy. his influence is also evident in the repeated recognition he received at prestigious national and international conferences, positioning him as a leading voice Cancer in neurovascular translational research. the framework he established for genetic-based intervention selection has potential parallels with feedback and adaptive systems in power electronics, reflecting the precision and personalization he brings to neurology.

🏆 Academic cites and recognition

Dr. Yoshimoto’s excellence has been widely acknowledged. he received the paul dudley white international scholar award from the american heart association in 2021 and multiple presentation awards at the japan stroke society and japanese society of neuroendovascular therapy (jsnet). notably, he received teaching awards and outstanding paper honors, reinforcing his role Cancer as both a scholar and mentor. these accolades validate the academic rigor and practical relevance of his work, particularly his contributions to stroke genetics and device selection.

🔬 Legacy and future contributions

Dr. Yoshimoto is poised to continue shaping the future of stroke research with a strong emphasis on personalized medicine. he aims to refine and implement his clot removal device selection algorithm into broader clinical practice. further integration of genetic biomarkers into real-time therapeutic decision-making is expected. his work not only improves outcomes for stroke patients but also sets a model for interdisciplinary research convergence, similar to how power electronics evolved by merging physics, control theory, and electrical engineering.

Notable Publication

  • Title: Relationship Between RNF213 p.R4810K and Echocardiographic Findings in Patients with Cerebrovascular Diseases: A Multicenter Prospective Cohort Study
    Author(s): Kotaro Noda, Yorito Hattori, Tatsuya Nishii, Yoshikazu Nakaoka, Masafumi Ihara
    Journal: Journal of the American Heart Association, 2025

  • Title: Deep learning-based post hoc denoising for 3D volume-rendered cardiac CT in mitral valve prolapse
    Author(s): Tatsuya Nishii, Tomoro Morikawa, Hiroki Nakajima, Satsuki M. Fukushima, Tetsuya Fukuda
    Journal: International Journal of Cardiovascular Imaging, 2025

  • Title: Evaluation of the Efficacy and Accuracy of Super-Flexible Three-Dimensional Heart Models of Congenital Heart Disease Made via Stereolithography Printing and Vacuum Casting: A Multicenter Clinical Trial
    Author(s): Isao Shiraishi, Masaaki Yamagishi, Takaya Hoashi, Toshiaki Hisada, Kenichi Kurosaki
    Journal: Journal of Cardiovascular Development and Disease, 2024

  • Title: Pericardial adhesion and performance of hemodynamically significant constrictive pericarditis using cine magnetic resonance feature tracking
    Author(s): Yasutoshi Ohta, Midori Fukuyama, Yoshiaki Morita, Hiroki Horinouchi, Tetsuya Fukuda
    Journal: International Journal of Cardiovascular Imaging, 2024

  • Title: Laterality of CT-measured hepatic extracellular volume fraction in patients with chronic thromboembolic pulmonary hypertension
    Author(s): Tatsuya Nishii, Hiroki Horinouchi, Takara Namboku, Takeshi Ogo, Tetsuya Fukuda
    Journal: International Journal of Cardiovascular Imaging, 2024

  • Title: Covering the intercostal artery branching of the Adamkiewicz artery during endovascular aortic repair increases the risk of spinal cord ischemia
    Author(s): Yoshimasa Seike, Tatsuya Nishii, Kazufumi Yoshida, Tetsuya Fukuda, Hitoshi Matsuda
    Journal: JTCVS Open, 2024

Assoc. Prof. Dr. Jun Xiu sheng – Cancer treatment – Best Researcher Award

Assoc. Prof. Dr. Jun Xiu sheng - Cancer treatment - Best Researcher Award

The First Affiliated Hospital of Dalian Medical University - China 

Author Profile 

SCOPUS 

ORCID 

🎓 Early academic pursuits

Jun Xiu sheng began his academic journey with a strong foundation in clinical medicine. from 2006 to 2011, he pursued a seven-year undergraduate program in clinical medicine at dalian medical university, followed by graduate studies from 2011 to 2013 at the same institution. in 2013, he embarked on a ph.d. in oncology at the graduate school of dalian medical university, sharpening his focus on cancer biology and therapy. his academic path was further enriched through a prestigious exchange scholar program at the medical university of wisconsin, usa, from 2015 to 2016, where he gained international exposure and research insight.

🩺 Professional endeavors

After completing his advanced education, jun xiu sheng joined the first affiliated hospital of dalian medical university. he served as a resident in the department of radiotherapy from 2016 to 2018 and quickly rose through the ranks to become an attending physician (2018–2020). since december 2020, he has held the position of deputy chief physician, where he also serves as an associate professor. his clinical expertise lies in radiation oncology, contributing to the development of novel therapeutic strategies in cancer care. jun xiu sheng’s interest in interdisciplinary approaches, including those inspired by power electronics systems, has made his clinical methods highly adaptive and innovative.

🔬 Contributions and research focus

With a ph.d. in oncology, jun xiu sheng has dedicated his research efforts to understanding the molecular and cellular mechanisms behind tumor resistance and radiotherapy. his recent work explores how melatonin modulates rna splicing in esophageal cancer cells, potentially increasing radiotherapy sensitivity. melatonin, known for its use in treating central nervous system Cancer treatment diseases, has shown promise in suppressing tumor growth. through bioinformatics and rna-seq analysis, jun xiu sheng has investigated the role of variable splicing in radiation resistance, aiming to unlock therapeutic pathways to improve cancer treatment outcomes. integrating ideas from power electronics systems, he also explores regulatory networks in tumor biology.

🌍 Impact and influence

Jun Xiu sheng’s research has not only advanced our understanding of cancer biology but also influenced therapeutic strategies in radiation oncology. by uncovering mechanisms related to rna Cancer treatment variable splicing and the effects of melatonin on tumor cells, he has provided critical insight into resistance pathways. his collaborative roles in national-level projects, including the national natural science foundation of china, have elevated his profile within the academic and medical communities. his interdisciplinary thinking, including applying models from power electronics, offers new paradigms in cancer signal processing and therapy modulation.

📚 Academic cites

Jun Xiu sheng has participated in several major research projects. he contributed to a study on circular rna generation funded by the national natural science foundation of china, and another Cancer treatment on the function of rna variable splicing in tumor radiotherapy resistance. as a principal investigator, he led projects on aspirin-induced rna splicing in lung cancer and on the immune regulation of head and neck squamous cell carcinoma (hnscc). his ongoing research into esophageal cancer immunotherapy and prognosis demonstrates a sustained commitment to scholarly contribution and scientific innovation.

🧬 Legacy and future contributions

Looking forward, jun xiu sheng is committed to deepening his exploration of tumor microenvironments, radiotherapy resistance mechanisms, and immune system interactions in cancer. his current projects funded by liaoning provincial programs and education departments reflect his active role in shaping the future of oncology. he envisions integrating computational and systemic models—akin to feedback loops found in power electronics—to decode complex biological responses in tumors. his legacy will be defined by a blend of rigorous scientific inquiry, clinical excellence, and forward-thinking applications in precision medicine.

Notable Publications 

Title: The role of oncostatin M in esophageal cancer and its potential as a prognostic marker
Author(s): Guangxiang Ding, Xianwei Li, Hongtao Yin, Bing Sun, Junxiu Sheng
Journal: Computers in Biology and Medicine, 2025

Dr. FrĂ©dĂ©rique Vegran – immuno oncology –  Best Researcher Award

Dr. Frédérique Vegran - immuno oncology -  Best Researcher Award

INSERM - France

Author Profile 

GOOGLE SCHOLAR 

🎓 Early academic pursuits

Frédérique Vegran began her scientific journey with a strong foundation in cellular and molecular biology, earning her phd in this domain. during her early academic years, she exhibited a keen interest in understanding cellular behavior under varying physiological conditions. this led her to pursue advanced studies and training in belgium, where she spent three years as a post-doctoral researcher. her research during this time revolved around the tumor microenvironment, hypoxia, and metabolic regulation—areas that laid the groundwork for her future focus in immuno-oncology, a field now evolving alongside advancements in power electronics and biotechnology integration.

đź§Ş Professional endeavors

Currently a full-time research scientist at inserm umr1231 in dijon, france, frédérique vegran has established herself as a leading figure in immuno-oncology. her professional tenure is marked by active involvement in cutting-edge research aimed at enhancing anti-tumor immune responses. she has supervised multiple phd candidates and participated in thesis evaluation committees, highlighting her commitment to nurturing future generations of scientists. her involvement in research also bridges academic curiosity with translational potential—something akin to the precision and adaptability found in modern power electronics systems.

🔬 Contributions and research focus

Vegran’s groundbreaking contributions have significantly advanced our understanding of t cell biology in cancer. one of her landmark findings includes the role of il-1b in promoting the anti-tumor effect of th9 cells (nature immunology, 2013). she also revealed a novel transcriptional function of nlrp3 in th2 cells (nature immunology, 2015), and more recently, identified the immuno oncology regulatory role of nlrp3 in th17 differentiation and its acquisition of treg-like properties within tumor environments (cellular and molecular immunology, 2025). such insights have reinforced the importance of targeted immune modulation—an idea resonating with the fine-tuning concepts used in power electronics.

🌍 Impact and influence

Her influence extends beyond publications, with an h-index of 37 and i10 index of 52, demonstrating consistent citation and global recognition of her work. having authored over 67 peer- immuno oncology reviewed articles, including in top-tier journals, frédérique vegran continues to impact the scientific discourse in immuno-oncology. her discoveries have paved new avenues for therapeutic strategies, inspiring researchers globally to explore the interplay between immune cells and cancer. her professional memberships with the french society of immunology (sfi) and the french society for immunotherapy of cancer (fitc) further signify her standing in the field.

📊 Academic cites

Vegran’s academic output is notable with 67 journal publications indexed in scopus and sci, alongside 8 completed and 3 ongoing research projects. she has contributed to 3 immuno oncology consultancy/industry-related projects and has 2 patents published, highlighting her dual focus on innovation and application. although she has not authored books, her work stands as a valuable reference across the immunological and oncological academic landscapes.

🧬 Legacy and future contributions

Frédérique Vegran’s legacy lies in the transformative nature of her research on immune modulation in cancer. her consistent engagement in phd mentorship, cutting-edge experimentation, and scientific evaluation sets a strong example for academic leadership. looking ahead, her research is poised to further decode immune-cancer interactions, potentially contributing to the development of novel therapeutic interventions that integrate cellular biology with advanced technologies, much like how power electronics revolutionized modern engineering systems.

Notable Publications 

  1. Title: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
    Authors: P. Sonveaux, F. Végran, T. Schroeder, M.C. Wergin, J. Verrax, Z.N. Rabbani, ...
    Journal: The Journal of Clinical Investigation

  2. Title: Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-ÎşB/IL-8 pathway that drives tumor angiogenesis
    Authors: F. Végran, R. Boidot, C. Michiels, P. Sonveaux, O. Feron
    Journal: Cancer Research

  3. Title: Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
    Authors: M. Bruchard, G. Mignot, V. Derangère, F. Chalmin, A. Chevriaux, F. Végran, ...
    Journal: Nature Medicine

  4. Title: Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis
    Authors: P. Sonveaux, T. Copetti, C.J. De Saedeleer, F. Vegran, J. Verrax, ...
    Journal: PLOS ONE

  5. Title: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation
    Authors: M. Bruchard, C. Rebé, V. Derangère, D. Togbé, B. Ryffel, R. Boidot, ...
    Journal: Nature Immunolog